Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Kamrul IslamFekade Bruck SimeSteven C WallisMichelle J BauerBrian M FordePatrick N A HarrisTahmina ShirinZakir H HabibMeerjady S FloraJason Alexander RobertsPublished in: The Journal of antimicrobial chemotherapy (2022)
Our study suggests piperacillin/tazobactam may be a potential alternative to carbapenems to treat urosepsis caused by ESBL-producing E. coli, although clinical trials with robust design are needed to confirm non-inferiority of outcome.